Epigenetics of estrogen receptor-negative primary breast cancer

Expert Review of Molecular Diagnostics

Volumn 12, Issue 4, 2012, Pages 371-382

  Huynh, Kelly T ^a   Chong, Kelly K ^a   Greenberg, Edward S ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

biomarkers; breast cancer; diagnosis; epigenetics; estrogen receptor; methylation; microRNA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANASTROZOLE; AZACITIDINE; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; MICRORNA; MICRORNA 10B; MICRORNA 125B; MICRORNA 155; PANOBINOSTAT; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VORINOSTAT; ZEBULARINE;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CARCINOMA IN SITU; CELL ADHESION; CHROMOSOMAL INSTABILITY; CPG ISLAND; DISEASE COURSE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DNA METHYLATION; DNA REPAIR; DNA SEQUENCE; EPIGENETICS; EUCHROMATIN; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENETIC REGULATION; HISTONE MODIFICATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MELANOMA; METHYLATION; MORTALITY; MYELODYSPLASTIC SYNDROME; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE RISK; REVIEW; TUMOR GROWTH;

BREAST NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN;

EID: 84861419487     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.26     Document Type: Review

References (89)

1. American Cancer Society. Cancer Facts Figures. American Cancer Society, GA, USA, 9 (2009
2. Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J. Mammary Gland Biol. Neoplasia 14(1), 67-78 (2009
3. Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin. Cancer Biol. 19(3), 165-171 (2009
4. Duffy MJ. Estrogen receptors: role in breast cancer. Crit. Rev. Clin. Lab. Sci. 43(4), 325-347 (2006
5. Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev. 29(5), 419-426 (2005
6. Li Q, Eklund AC, Juul N et al. Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS One 5(12), e15031 (2010
7. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28(16), 2784-2795 (2010
8. Saxena NK, Sharma D. Epigenetic reactivation of estrogen receptor: promising tools for restoring response to endocrine therapy. Mol. Cell. Pharmacol. 2(5), 191-202 (2010
9. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 23(7), 781-783 (2009
10. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008
11. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330-339 (2011
12. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol. Biol. 9, 76 (2008
13. Frankel LB, Christoffersen NR, Jacobsen A et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283(2), 1026-1033 (2008
14. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065-7070 (2005
15. Si ML, Zhu S, Wu H et al. miR-21- mediated tumor growth. Oncogene 26(19), 2799-2803 (2007
16. Sunami E, Shinozaki M, Sim MS et al. Estrogen receptor and HER2/n status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res. 10(3), R46 (2008
17. van Hoesel AQ, van de Velde CJ, Kuppen PJ et al. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res. Treat. 131(3), 859-869 (2012
18. Schinke C, Mo Y, Yu Y et al. Aberrant DNA methylation in malignant melanoma. Melanoma Res. 20(4), 253-265 (2010
19. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007
20. Portela A, Esteller M. Epigenetic modifications and human disease. J. Nat. Biotechnol. 28(10), 1057-1068 (2010
21. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 31(1), 27-36 (2010
22. Huang TH, Esteller M. Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb. Perspect. Biol. 2(9), A004515 (2010
23. Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol. Oncol. 4(3), 242-254 (2010
24. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 9(12), 1879-1902 (2008
25. Pathiraja TN, Stearns V, Oesterreich S. Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response. J. Mammary Gland Biol. Neoplasia 15(1), 35-47 (2010
26. Shinozaki M, Hoon DS, Giuliano AE et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin. Cancer Res. 11(6), 2156-2162 (2005
27. Sharma G, Mirza S, Parshad R et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin. Biochem. 43(4-5), 373-379 (2010
28. Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann. N. Y. Acad. Sci. 1137, 171-174 (2008
29. Jenuwein T, Allis CD. Translating the histone code. Science 293(5532), 1074-1080 (2001
30. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007
31. Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298(5595), 1039-1043 (2002
32. Kuzmichev A, Nishioka K, Erdjument- Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein. Genes Dev. 16(22), 2893-2905 (2002
33. Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871-874 (2006
34. Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Development 132(21), 4645-4652 (2005
35. Davis BN, Hata A. microRNA in cancer - the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer 1(11), 1100-1114 (2010
36. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 66(15), 7390-7394 (2006
37. Asaga S, Kuo C, Nguyen T et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 57(1), 84-91 (2011
38. Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14(11), 2348-2360 (2008
39. Lapidus RG, Nass SJ, Butash KA et al. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res. 58(12), 2515-2519 (1998
40. Ottaviano YL, Issa JP, Parl FF et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54(10), 2552-2555 (1994
41. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 55(11), 2279-2283 (1995
42. Yan L, Nass SJ, Smith D et al. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-a(ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther. 2(5), 552-556 (2003
43. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25(3), 269-277 (2000
44. Leu YW, Yan PS, Fan M et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 64(22), 8184-8192 (2004
45. Pandey DP, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor amRNA. Mol. Cell. Biol. 29(13), 3783-3790 (2009
46. Park SY, Kwon HJ, Lee HE et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 458, 73-84 (2011
47. Melnikov AA, Scholtens DM, Wiley EL, Khan SA, Levenson VV. Array-based multiplex analysis of DNA methylation in breast cancer tissues. J. Mol. Diagn. 10(1), 93-101 (2008
48. Chen KM, Stephen JK, Raji U, Worsham MJ. Delineating an epigenetic continuum for initiation, transformation and progression to breast cancer. Cancers (Basel) 3(2), 1580-1592 (2011
49. Pasquali L, Bedeir A, Ringquist S et al. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett. 257(1), 136-144 (2007
50. Hoque MO, Prencipe M, Poeta ML et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol. Biomarkers Prev. 18(10), 2694-2700 (2009
51. Marzese DM, Gago FE, Vargas-Roig LM, Roqué M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol. Cell. Probes 24(5), 271-280 (2010
52. van Hoesel AQ, van de Velde CJH, Kuppen PJK et al. Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res. Treat. doi:10.1007/s10549-012- 2038-0 (2012) (Epub ahead of print
53. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999
54. Kusano M, Toyota M, Suzuki H et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106(7), 1467-1479 (2006
55. Tanemura A, Terando AM, Sim MS et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 15(5), 1801-1807 (2009
56. Fang F, Turcan S, Rimner A et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 3(75), 75ra25 (2011
57. Jing F, Yuping W, Yong C et al. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol. 31(4), 321-331 (2010
58. Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer 7, 15 (2008
59. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann. N. Y. Acad. Sci. 1014, 155-163 (2004
60. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol. 1(6), A003129 (2009
61. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am. J. Clin. Pathol. 115(1), 85-98 (2001
62. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 92(3), 404-408 (2001
63. Caldeira JRF, Prando EC, Quevedo FC, Neto FAM, Rainho CA, Rogatto SR. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 6, 48 (2006
64. Nass SJ, Herman JG, Gabrielson E et al. Aberrant methylation of the estrogen receptor and E-cadherin in 5' CpG islands increases with malignant progression in breast cancer. Cancer Res. 60(16), 4346-4348 (2000
65. Zou D, Yoon HS, Perez D, Weeks RJ, Guilford P, Humar B. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J. Pathol. 218(2), 265-272 (2009
66. de Maat MF, Narita N, Benard A et al. Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. Am. J. Pathol. 177(5), 2347-2356 (2010
67. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59(21), 5438-5442 (1999
68. Feng W, Shen L, Wen S et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 9(4), R57 (2007
69. Holm K, Hegardt C, Staaf J et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 12(3), R36 (2010
70. Flanagan JM, Cocciardi S, Waddell N et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am. J. Hum. Genet. 86(3), 420-433 (2010
71. Lowery AJ, Miller N, Devaney A et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/n receptor status in breast cancer. Breast Cancer Res. 11(3), R27 (2009
72. Orlando L, Schiavone P, Fedele P et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat. Rev. 36(Suppl. 3), S67-S71 (2010
73. Mori T, Martinez SR, O'Day SJ et al. Estrogen receptor-amethylation predicts melanoma progression. Cancer Res. 66(13), 6692-6698 (2006
74. Cittelly DM, Das PM, Spoelstra NS et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer 9, 317 (2010
75. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin. Cancer Res. 15(12), 3938-3946 (2009
76. Kantarjian HM, O'Brien S, Huang X et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109(6), 1133-1137 (2007
77. Munster PN, Thurn KT, Thomas S et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104(12), 1828-1835 (2011
78. Fan J, Yin WJ, Lu JS et al. ER anegative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol. 134(8), 883-890 (2008
79. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66(12), 6370-6378 (2006
80. Keen JC, Yan L, Mack KM et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor a(ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res. Treat. 81(3), 177-186 (2003
81. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor a(ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther. 6(1), 64-69 (2007
82. Yang X, Ferguson AT, Nass SJ et al. Transcriptional activation of estrogen receptor ain human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60(24), 6890-6894 (2000
83. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med. J. 50(4), 455-463 (2009
84. Elsheikh SE, Green AR, Rakha EA et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 69(9), 3802-3809 (2009
85. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100(20), 11606-11611 (2003
86. Xiong J, Yu D, Wei N et al. An estrogen receptor asuppressor, microRNA-22, is downregulated in estrogen receptor a-positive human breast cancer cell lines and clinical samples. FEBS J. 277(7), 1684-1694 (2010
87. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-a(ERa) and represses ERamessenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 21(5), 1132-1147 (2007
88. Zhao JJ, Lin J, Yang H et al. MicroRNA-221/222 negatively regulates estrogen receptor aand is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283(45), 31079-31086 (2008
89. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat. 120, 581-592 (2010